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Abstract 
Background: The estimates of risk of malaria in early childhood are imprecise given the current entomologic and 
parasitological tools. Thus, the utility of anti‑Anopheles salivary gSG6‑P1 peptide antibody responses in measuring 
exposure to Anopheles bites during early infancy has been assessed.
Methods: Anti‑gSG6‑P1 IgG and IgM levels were evaluated in 133 infants (in Benin) at three (M3), six (M6), nine (M9) 
and 12 (M12) months of age. Specific IgG levels were also assessed in their respective umbilical cord blood (IUCB) and 
maternal blood (MPB).
Results: At M3, 93.98 and 41.35% of infants had anti‑gSG6‑P1 IgG and IgM Ab, respectively. Specific median IgG and 
IgM levels gradually increased between M3 and M6 (p < 0.0001 and p < 0.001), M6–M9 (p < 0.0001 and p = 0.085) 
and M9–M12 (p = 0.002 and p = 0.03). These levels were positively associated with the Plasmodium falciparum infec‑
tion intensity (p = 0.006 and 0.003), and inversely with the use of insecticide‑treated bed nets (p = 0.003 and 0.3). 
Levels of specific IgG in the MPB were positively correlated to those in the IUCB (R = 0.73; p < 0.0001) and those at M3 
(R = 0.34; p < 0.0001).
Conclusion: The exposure level to Anopheles bites, and then the risk of malaria infection, can be evaluated in young 
infants by assessing anti‑gSG6‑P1 IgM and IgG responses before and after 6‑months of age, respectively. This tool can 
be useful in epidemiological evaluation and surveillance of malaria risk during the first year of life.
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Background
In the absence of effective vaccines, malaria control and 
prevention strategies are primarily based on the wide-
spread use of effective drugs and vector control by insec-
ticide-treated bed nets (ITNs) and indoor residual sprays 
[1–3]. Such interventions are associated with recent 
decline in malaria burden across a range of settings [4–6]. 
However, malaria incidence and risk are static or increas-
ing in several African countries, including the Republic of 
Benin, where the disease is still the first leading cause of 
child morbidity and mortality [7].
Naïve newborns are at increased risk of malaria infec-
tion during the first year of life in endemic areas [8–10]. 
Newborn exposure to malaria has traditionally been 
assessed using entomological and parasitological meth-
ods. However, these methods are labour-intensive and 
difficult to sustain especially in low transmission or expo-
sure contexts [11, 12]. In addition, these methods are typ-
ically used at the community level measure and do not 
target the individual [13]. Moreover, these methods typi-
cally exclude infants or newborns because of numerous 
ethical concerns [14, 15]. Evaluating the risk of malaria 
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in vulnerable infants is not only challenging but also 
requires new tools [16, 17].
Improving an understanding of human-Anopheles 
interactions can potentially provide a promising alterna-
tive [18, 19]. Plasmodium spp. are transmitted to humans 
by the saliva of infected-female Anopheles mosquitoes 
during a blood meal. Injected mosquito salivary mol-
ecules facilitate the mosquito blood-feeding activity both 
by counteracting the human haemostatic and inflamma-
tory reactions and by modulating its innate and adap-
tive immune responses [20, 21]. Following mosquito 
infecting as well as not-infecting bites, humans produce 
immunoglobulin G (IgG), M (IgM), and/or E (IgE) spe-
cific to injected mosquito salivary proteins [22–24]. Such 
humoral responses may be a marker of human exposure 
to vector bites and pathogens associated with mosquito-
borne diseases [25–30].
A specific and highly conserved Anopheles gambiae 
salivary gland protein-6 peptide 1 (gSG6-P1) antigen 
has been validated as a biomarker of Anopheles bites 
[13]. The anti-gSG6-P1 IgG response has been associ-
ated with local exposure level to An. gambiae s.l. and 
Anopheles funestus s.s. bites in zones with various trans-
mission intensities [22, 31–33]. Moreover, anti-gSG6-P1 
IgG responses have been shown to reflect the success of 
ITN-based [31, 34] and other [34] malaria vector control 
methods in that they diminish quite rapidly when expo-
sure level drops [31]. However, this tool has not yet been 
tested in vulnerable young infants (<1-year old), there-
fore limiting its field application to malaria epidemiologi-
cal studies or surveys.
The present study aimed to evaluate and to follow, dur-
ing the first months of life, the acquisition level of human 
IgM and IgG responses to gSG6-P1 in southern Benin. 
Associations between specific gSG6-P1 IgG and IgM 
responses and parasitological and entomological param-
eters were evaluated. Whether mothers provide their 
infant with specific IgG through fetal-maternal transfer 
was also investigated.
Methods
Study area
The study was conducted in the district of Tori Bossito, 
a rural area located on the coastal plain of south Benin, 
40 km northwest of Cotonou (the economic capital city). 
It is a sub-tropical area with an annual average rainfall 
of 1,100  mm. There are two rainy seasons: April–July 
and October–November. The distribution of rainfalls, 
maximal during the two rainy seasons, was heterogene-
ous over the area. Average temperatures monthly var-
ied between 27 and 31°C. Anopheles gambiae s.s. and 
An. funestus, the most abundant anopheline species, are 
the major vectors for the transmission of Plasmodium 
falciparum, the major human malaria parasite in this 
region [35, 36]. A recent study has described an average 
annual P. falciparum entomological inoculation rate of 
15.5, with important time and space variations depend-
ing on villages [37]. Anopheles nili, Anopheles pharoensis 
and Anopheles leesoni, also locally present, are not yet 
associated with malaria transmission [36].
Study design, population and sampling
The study included nine villages (Avame Centre, Gbed-
jougo, Houngo, Anavie, Dohinoko, Gbetaga, Tori Cada 
Centre, Zebe, and Zoungoudo) distributed within three 
maternity hospitals (MHs: Avame, Cada and Gare) pro-
viding birth attendance and primary health care. Women 
who attended the maternity hospitals for antenatal care 
were asked to enter into the study and were recruited from 
anytime after the 7th month of pregnancy. Inclusion crite-
ria were to: (1) live in one of the nine villages; (2) have no 
intention to move within the next 12 months; and, (3) plan 
to deliver at the maternity hospital. At delivery, mater-
nal peripheral (MPB) and infant umbilical cord (IUCB) 
blood spots were collected on filter papers (Whatman No 
1, Saint-Louis, MO, USA). After delivery, newborns were 
actively followed monthly over the subsequent 12 months. 
Capillary blood on filter paper and venous blood for 
smears (thick blood smears) were collected every 3 months 
(M3, M6, M9, and M12) for each live newborn to study the 
kinetics of antibody responses to gSG6-P1 peptide and to 
determine the presence and/or intensity of P. falciparum 
infections. Parasite density (parasitaemia) was calculated 
as the number of P. falciparum (99% of identified Plasmo-
dium) parasites per microlitre of blood; mean parasitaemia 
values (x + 1) were calculated. Mothers were asked to fill 
out questionnaires, including the use of ITNs and any clin-
ical sign of the malaria for themselves and their babies. A 
birth cohort was then set up in July 2007 and recruitment 
performed until July 2008 as previously described [37].
The IRD Consultative Committee on Professional Con-
duct and Ethics (5 May, 2008) and the Ethical Committee 
of the Faculté des Sciences de la Santé of the University of 
Abomey-Calavi in Benin approved the study. All neces-
sary permits were obtained for the described field stud-
ies. Informed written consent in French and Fon (major 
spoken language in the studied region) was obtained 
from the mothers.
Immunoassays were performed for 133 infants who 
completed a cord blood and the all four three-monthly 
blood spot samplings during the first 12  months of life 
follow-up.
Prediction of spatiotemporal risk of malaria transmission
Entomological data (by human landing catch of mosqui-
toes) were collected every 6  weeks on three successive 
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nights from July 2007 to July 2008 at four catch houses 
(four indoors and four outdoors) in each village, as pre-
viously described [38]. A statistical model predicting the 
spatiotemporal transmission of malaria at the household 
level in all nine villages was then developed based on 
correlation results between Anopheles density and cli-
matic/environmental factors [38], allowing comparisons 
between the individual risk of malaria transmission data 
from that model to anti-gSG6-P1 IgG and IgM Ab levels.
Salivary peptide gSG6‑P1
The gSG6-P1 peptide was designed using bioinformat-
ics to maximize its Anopheles specificity, synthesized and 
purified by Genepep SA (Saint Jean de Vedas, Herault, 
France). It was used for immunological tests (ELISA) as 
previously described [13, 32].
Human IgG and IgM assays by indirect ELISA
Standardized dried blood spots were eluted as previ-
ously described [28]. ELISAs were carried out on blood 
spot eluates to assay IgG and IgM responses to gSG6-P1. 
Briefly, Maxisorp plates (Nunc, Roskilde, Denmark) were 
coated with gSG6-P1 antigen (20 μg/mL) in PBS. Plates 
were blocked using 300  µL of Protein-Free Blocking-
Buffer (Pierce, Thermo Scientific, France) for 45  min at 
37°C. Eluates were diluted 1/40 (IgG) or 1/20 (IgM) in 
PBS-Tween-1% and incubated in duplicate at 4°C over-
night. Monoclonal mouse biotinylated Ab against human 
IgG or IgM (BD Pharmingen, San Diego, CA, USA) were 
incubated at 1/2,000 (IgG) or 1/500 (IgM) dilution. Per-
oxidase-conjugated streptavidin (Amersham, Les Ulis, 
France) was then added (1/2,000 for IgG and 1/500 for 
IgM). Colorimetric development was carried out using 
ABTS (2,2’-azino-bis (3-ethylbenzothiazoline-6-sul-
fonic acid) diammonium; Sigma, St Louis, MO, USA) in 
50 mM citrate buffer (pH 4) containing 0.003% H2O2. The 
optical density (OD) was measured at 405 nm. In paral-
lel, each test sample was assessed in a blank well contain-
ing no gSG6-P1 antigen (ODn). Results were expressed as 
the ΔOD value: ΔOD = ODx − ODn, where ODx rep-
resents the mean of individual OD in both antigen wells. 
Anti-gSG6-P1 IgG and IgM levels were also assessed in 
14 non-Anopheles exposed individuals (negative controls) 
from northern France to calculate the immune response 
threshold (TR). The TR was calculated by the following 
formula: TR = mean (ΔODneg) + 3SD = for IgG for IgM. 
In the present study an IgG responder had a ΔODIgG 
> 0.204 and an IgM responder had a ΔODIgM > 0.288.
Statistical analysis
Data were analysed using R (version 2.14.1), and graphs 
were constructed with GraphPad Prism5® software (San 
Diego, CA, USA). An simple linear mixed effect (LME) 
regression model was constructed to determine the cor-
relation between anti-gSG6-P1 IgG or IgM response and 
each of potential epidemiological, biological and envi-
ronmental factors, such as age (M3, M6, M9, and M12), 
gender (male vs female), the season of sampling (end dry 
season: February to April; beginning rainy season: May to 
July; end rainy season: August to October; beginning dry 
season: November to January), P. falciparum prevalence 
(yes/no), P. falciparum infection intensity (continuous 
variable), bed net use (yes/no), and environmental risk 
of exposure (continuous variable). Then, a multivariate 
LME analysis was performed by including all explanatory 
variables that have shown significant (or close) p value in 
the univariate (simple) model. In this multivariate model, 
two random intercepts at individual and village levels 
were introduced, correcting then biological inter-individ-
ual and inter-village variations. Two or more percentages 
of immune responders were compared using the Fisher’s 
exact-test. Spearman rank correlations were used to esti-
mate the force of the association between specific IgG in 
the MPB, IUCB and M3-infants’ peripheral (M3) bloods.
Results
Evolution of specific IgG and IgM levels during the first 
year of life
At month 3 (M3), levels of specific gSG6-P1 IgG (Fig-
ure  1a) and IgM (Figure  1b) in the peripheral blood of 
infants were low [median IgG level (MIgG) =  0.383 and 
median IgM level (MIgM)  =  0.228]. Importantly, these 
levels of IgG and IgM gradually increased from M3 to 
M12 (MIgG = 0.721 and MIgM = 0.352), with intermediate 
values at M6 (MIgG = 0.527 and MIgM = 0.288) and M9 
(MIgG =  0.646 and MIgM =  0.326). The increase of spe-
cific IgG levels (Figure  1a) was significant between two 
successive sampled age periods: M3–M6 (p  <  0.0001), 
M6–M9 (p < 0.0001) and M9–M12 (p = 0.002). Similarly, 
specific IgM levels (Figure 1b) significantly increased only 
between M3 and M6 (p < 0.001) and M9–M12 (p = 0.03). 
No significant increase in specific IgM levels was noted 
between M6 and M9 (p = 0.085).
Interestingly, as observed for anti-gSG6-P1 IgG and 
IgM, the intensity of P. falciparum infection in infants 
(Figure 1c) and the predicted entomological risk of infant 
exposure to Anopheles bites (Figure 1d) were also low at 
M3 and increased from M3 to M12. However, the differ-
ence in the intensity of P. falciparum infection and the 
predicted entomological risk of exposure between any 
two consecutive age periods (M3–M6, M6–M9 and M9–
M12) were not significant, unlike that observed for anti-
gSG6-P1 Ab levels.
The percentages of IgG and IgM responders were 
calculated for the four time-sampling dates (Table  1). 
Results show that by M3, 94% of the infants were IgG 
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Figure 1 IgG and IgM responses to gSG6‑P1 salivary peptide, intensity of Plasmodium falciparum transmission and Anopheles exposure level in 
the first year of life. Individual IgG (1a) and IgM (1b) responses to the Anopheles gSG6‑P1 peptide biomarker are represented for infants in months 3 
(white), 6 (light-grey), 9 (dark-grey) and 12 (black box) after their birth. Boxes locate the middle 50% of the data; horizontal lines in the boxes indicate 
median values; lengths of boxes correspond to the inter‑quartile ranges. Horizontal black dotted lines represent the cut‑off of IgG (0.204) and IgM 
(0.288) responder. The intensity of P. falciparum infection (1c) and the entomological risk of malaria (1d) are also represented for the same four age‑
sampling periods. Vertical lines indicate confidence intervals of the mean values. Statistical significant differences between all age groups (multivari‑
ate linear mixed model analysis) are indicated.
Table 1 Percentages of IgG and IgM responders according to age and the place of birth/residence
The place of birth/residence was studied by combining infants of all ages (n = 532).
Variables Groups Individual Ab responders to gSG6‑P1 peptide
Percentage (%) of IgG responders Percentage (%) of IgM responders
Age M3 93.98 (125/133) 41.35 (55/133)
M6 97.74 (130/133) 50.37 (67/133)
M9 98.96 (131/133) 56.39 (75/133)
M12 98.96 (131/133) 65.41 (87/133)
Maternity hospitals Avame 97.87 (230/235) 17.02 (40/235)
Gare 93.11 (108/116) 89.65 (104/116)
Cada 98.37 (181/184) 76.63 (141/184)
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responders, and this increased to 98% by M6 and to 99% 
by M9–M12. The percentage of IgM responders was 
lower at M3 (41%), and gradually increased to 65% by 
M12 with values of 50% at M6 and 56% at M9.
Specific gSG6‑IgG levels according to maternity hospital 
of delivery
Assuming that each pregnant woman delivered her baby 
at the closest maternity hospital, Immunological data 
were analysed based on the hospital of delivery. Avame, 
Gare and Cada received pregnant women from three 
(Avame centre, Gbedjougo and Houngo), two (Dohi-
noko and Gbetaga) and four villages (Anavie, Cada, Zebe 
and Zoungoudo), respectively. The M3 levels of IgG and 
IgM (Figure 2) and the percentage of IgM responders at 
M3 (Table  1) were lower in Avame compared to Gare 
(p = 0.0013, p < 0.0001 and p < 0.0001, respectively) or to 
Cada (p < 0.0001 for all three), although the percentage 
of IgG responders (Table  1) was not significantly differ-
ent among the three locations of birth. Median IgG levels 
did not differ between Gare and Cada (p = 0.47), in con-
trast to the median IgM levels, which were higher in Gare 
(p = 0.0008).
The profile of median of specific Ab levels during the 
first life year was similar in the three MHs: a gradual 
increase from M3 to M12 (Figure 2). However, some dif-
ferences between two successive age-sampling periods 
were observed. In detail, in Avame (Figure 2a) where anti-
gSG6-P1 Ab responses were lower, IgG levels increased 
significantly between M3 and M6 (p < 0.0001), M6–M9 
(p < 0.0001), M9–M12 (p < 0.05), and IgM levels between 
M3 and M6 (p  <  0.05), M9–M12 (p  <  0.01). However, 
IgG and IgM levels significantly increased only between 
M3 and M6 in Gare (p < 0.001 for IgG; Figure 2b) and in 
Cada (p < 0.0001 and p < 0.001 respectively; Figure 2c).
Age, intensity of Plasmodium falciparum infection, use 
of vector control and exposure to Anopheles bites: main 
factors of variation of anti‑gSG6‑P1 IgG and IgM levels
Independent of location and individual cofactors (ran-
dom intercepts at individual and village levels), both 
individual IgG and IgM responses to gSG6-P1 were 20 
and 8% higher at M6 (regression coefficient (RE) = 1.20 
and p < 0.0001, RE = 1.08 and p = 0.0117, respectively), 
34 and 12% at M9 (RE = 1.34 and p < 0.0001, RE = 1.12 
and p  <  0.0001, respectively) and 39 and 16% at M12 
(RE =  1.39 and p  <  0.0001, RE =  1.16 and p  <  0.0001, 
respectively) compared to M3 (Table 2). Specific IgG and 
IgM levels were also positively associated with the den-
sity of P. falciparum infection (RE = 1.03 and p = 0.0065, 
RE  =  1.03 and p  =  0.0037, respectively). In contrast, 
Figure 2 Evolution of gSG6‑P1‑specific IgG and IgM in the maternity 
hospital of infants’ birth. The evolution of IgG (solid line) and IgM 
(dotted line) responses to gSG6‑P1 Anopheles antigen is represented 
for infants in Tori Avame (a), Tori Gare (b) and Tori Cada (c). The sig‑
nificance level of the difference of specific Ab level between two suc‑
cessive age‑periods is indicated by “*” (“*”, “**” and “***” mean p < 0.05, 
p < 0.001 and p < 0.0001, respectively).
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anti-gSG6-P1 IgG responses significantly decreased 
with the use of vector control (ITNs) (RE  =  0.47 and 
p  =  0.0037). Finally, no significant variation of specific 
gSG6-P1 IgG or IgM levels was observed according to 
seasonality, the predictive risk of exposure to malaria or 
the prevalence of infection with P. falciparum (Table 2).
Evidence of mother‑to‑child transmission of anti‑gSG6‑P1 
IgG
As mentioned before, the percentage of specific IgG 
responders was surprisingly high (93.98%), and con-
siderably higher (p  <  0.0001) than that of anti-gSG6-P1 
IgM responders (41.35%). In addition, a positive asso-
ciation was observed between specific IgG levels in the 
MPB and the IUCB (Spearman R  =  0.73; p  <  0.0001; 
Figure  3a), in the IUCB and the peripheral blood of 
M3-infants (R = 0.43; p < 0.0001; Figure 3b), and in the 
MPB and the peripheral blood of M3-infants (R = 0.34; 
p  <  0.0001; Figure  3c). Moreover, a positive association 
was observed between specific IgG levels in the MPB 
and the M3-infant bloods in Avame (Spearman R = 0.36; 
p =  0.006) and Cada (R =  0.40; p =  0.005), and not in 
Gare (R = 0.07; p = 0.7).
Discussion
This study reports the presence of IgG and IgM Ab spe-
cific to gSG6-P1, a salivary biomarker of Anopheles bites, 
in the blood of Beninese infants. A major point is that 
levels of such IgG and IgM responses gradually increased 
from three to 12 months of age, in parallel with the inten-
sity of infection with P. falciparum and the predicted ento-
mological risk of exposure to Anopheles bites. These data 
extend to infants the utility of such a biomarker and show 
also that mother-to-child transplacental transfer of IgG 
specific to a salivary protein of a blood-feeding arthropod 
occurs. This transfer, however, could cause an overesti-
mate of the risk of malaria exposure or transmission dur-
ing early childhood in a high endemic malaria area.
Table 2 Linear Mixed-Effects (LME) model to study anti-gSG6-P1 response according to age, gender, seasonality, vector 
control, location and Plasmodium falciparum infection
The classes of variables with significant p value are highlighted in italic
The intercept is the constant value when all independent variables are zeros (e.g. the value of median Ab response in someone with no risk factors). Random effects 
of the model were estimated at individual and village levels in the form of standard deviation. The estimated coefficient, its confidence interval and the degree of 
signification (P-value) are indicated. A positive regression coefficient means that the explanatory variable increases the probability of Ab response to gSG6-P1, while a 
negative regression coefficient means the contrary. 
Anti‑gSG6‑P1 IgG response Anti‑gSG6‑P1 IgM response
Estimated coefficient (SE) P‑value Estimated coefficient (SE) P‑value
Fixed effects
 Intercept 0.57 (0.09) 0.0000 0.36 (0.06) 0.0000
 Age (months)
  3 (n = 133) – – – –
  6 (n = 133) 0.184 (0.024) 0.0000 0.081 (0.025) 0.0117
  9 (n = 133) 0.289 (0.025) 0.0000 0.110 (0.026) 0.0000
  12 (n = 133) 0.327 (0.026) 0.0000 0.152 (0.026) 0.0000
 Season
  Dry season 1 – – – –
  Dry season 2 0.57 (0.09) 0.1445 ‑0.001 (0.028) 0.9561
  Rain season 1 0.57 (0.09) 0.3689 ‑0.040 (0.044) 0.3590
  Rain season 2 0.57 (0.09) 0.7927 ‑0.029 (0.030) 0.3218
 Vector control
  No ITN – – – –
  ITN −0.075 (0.025) 0.0037 −0.023 (0.027) 0.3904
 Plasmodium prevalence
  Not infected – – – –
  Infected 0.016 (0.064) 0.8084 0.089 (0.068) 0.1943
 Plasmodium density 0.031 (0.011) 0.0065 0.031 (0.010) 0.0037
 Entomological risk of exposure −0.003 (0.004) 0.4677 0.009 (0.005) 0.0578
Random effects
 Village level 0.074 (0.045) – 0.091 (0.086) –
 Individual level 0.241(0.183) – 0.157 (0.202) –
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In the study, anti-gSG6-P1 IgG and IgM Ab were 
detected in respectively 93.98 and 41.35% of infants at 
3 months (M3) of age. Anopheles mosquitoes then early 
bite the majority of infants in these localities of south 
Benin. However, the pressure of mosquito bites they were 
exposed to at 3 months was not high, as pointed by the 
low median values of IgG (M = 0.383, slightly upper the 
‘TRIgG’) and IgM (M  =  0.228, under the TRIgM). These 
‘low’ endogenous M3-levels of plasma specific antibodies 
were not surprising, in that the newborn immune system 
is relatively considered as immature during early infancy 
[39–41]. In endemic malaria areas, young infants are pro-
gressively exposed to Anopheles bites, their salivary anti-
gens, and eventually the Plasmodium spp. they carry [42]. 
This is suggested by the correlation observed between 
anti-gSG6-P1 Ab and both the intensity of infection with 
P. falciparum and the entomological risk of infant expo-
sure to Anopheles bites [22, 26, 28, 33].
Specific IgG and IgM levels significantly differed based 
on the location of residence, suggesting spatial differ-
ences in human-Anopheles contact levels. Infants in the 
Avame area had lower specific IgG and IgM responses 
and presumably a lower contact level with Anopheles 
during their first year of life. This can be linked to a likely 
lower aggressiveness of Anopheles in this area, a higher 
protection level against vectors or different household 
characteristics (type, well-closed doors and windows) 
[22, 31–33, 38]. This might explain the slower gradual 
increase of specific IgG and IgM in Avame compared to 
Cada and Gare. The role of individual factors (genetic 
background, nutritional status or nocturnal activities) in 
that differential gradual acquisition cannot be excluded 
[37, 43, 44]. All this means that infants were more highly 
bitten by mosquitoes, acquired more rapidly maturity of 
immune system and synthetized more specific antibodies 
in Gare settings than in Avame and Cada.
Maternal IgG is provided to the infant by transplacen-
tal transport [9, 45]. This study describes the evidence of 
a mother-infant transplacental transfer of anti-gSG6-P1 
IgG, contributing to the high percentage of IgG infant 
responders at 3  months of age (about 94%). Maternal 
blood concentrations of specific IgG were positively cor-
related with respective umbilical cord and three-month 
old infant blood values. In addition, higher specific IgG 
levels were found in the maternal and cord blood of 
M3-infants with higher IgG titers, suggesting that the 
quantity of transferred specific IgG is dependent on the 
level in the mother that likely reflects the level of mater-
nal exposure to Anopheles bites. Despite this positive 
association, maternal levels of specific IgG transfer could 
not accurately predict the level of infant specific IgG. 
In addition, such transfer also depends on the placen-
tal integrity, IgG subclass and nature of antigen [9, 46]. 
Unfortunately, investigating the effects of such factors 
was not possible in this study.
For a reliable evaluation of the young infant-Anopheles 
contact level by using anti-gSG6-P1 IgG, the propor-
tion contributed from the mother must be considered. 
The linear regression analysis has estimated about 52 
and 21% of the maternal gSG6-P1-specific IgG found in 
blood of newborns just after delivery and at 3  months 
of life, respectively, indicating a rapid decline of mater-
nally transferred IgG [47, 48]. It also suggests that mater-
nally transferred IgG are probably cleared in the blood of 
infants by 6 months of age, suggesting that anti-gSG6-P1 
IgG should be more relevant as biomarker of infant expo-
sure to mosquito bites after 6  months of age. Another 
possibility would be to distinguish maternal and neonatal 
Figure 3 Correlations between specific IgG levels in the mothers’ peripheral blood, umbilical cord blood and blood of M3‑infants. Anti‑gSG6‑P1 IgG 
individual levels (black points) in the mothers’ peripheral blood (MPB) are correlated to those detected in the infants’ umbilical cord (IUCB; Figure 2a) 
and in the M3‑infants’ blood (Figure 2c). Specific IgG in the IUCB are correlated to those in M3‑infant blood (Figure 2b). The black solid line indicates 
the correlation line. The significance of the linear association between two compared parameters is indicated (Spearman correlation method).
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specific Ab in infant plasma by mass spectrometry [49], 
but such technology is unavailable in resource-limited 
countries. The third approach would be to use IgM Ab 
that form polymers (usually pentamers) in humans and 
does not cross the maternal-feta barrier [9, 50]. Inter-
estingly, the M3 proportion of infants presenting IgM 
against gSG6-P1 peptide (41.35%) was significantly lower 
than the percentage of those with specific IgG (93.98%). 
In addition, the highest percentage of IgM respond-
ers (89.65%) was obtained in Gare areas, where levels of 
mother specific IgG were not correlated to levels of IgG 
of their M3-infants, contrary to Avame and Cada areas. 
Moreover, no differences in IgM levels or percentage of 
responders were observed between two successive sam-
pling ages after 6 months of age, in contrast to IgG lev-
els. In infants older than 6  months, specific IgG levels 
were better at assessing exposure to Anopheles bites and 
the risk of malaria transmission. One hypothesis is that, 
depending on the level of exposure to mosquito bites, 
the initial anti-Anopheles saliva IgM response may have 
failed to switch to IgG after several weeks or months as 
has been shown previously for responses to P. falciparum 
antigens [50, 51]. Nevertheless, the kinetics of IgG (and 
subclasses) and IgM responses to gSG6-P1 salivary pep-
tide must be elucidated in additional studies.
Conclusion
In summary, individual exposure levels to Anopheles 
mosquito bites and therefore the risk for malaria trans-
mission in early infancy has been described in a malaria-
endemic area of Benin. Moreover, because of transfer of 
IgG specific to salivary gSG6-P1 Anopheles peptide from 
mother to infant there may be an overestimation of the 
utility of such a ‘biomarker’ early in infancy (less than 
3  months). To overcome that potential challenge, spe-
cific IgM and IgG isotypes may be assayed for in infants 
younger and older than 6 months, respectively.
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